Source:Instrument Family,Reprint is prohibited without authorization, and reprinting is allowed 24 hours later.

On March 26, GE Healthcare India subsidiary (hereinafter referred to as "GE India")Announced an investment of 80 billion rupees (approximately USD 960 million, RMB 6.93 billion) over the next five years.For manufacturing output and local R&D.

As part of the investment plan,GE Healthcare to Produce Discovery IQ PET/CT in India for Export to 15 Countries; Other High-End Technologies Including Revolution Aspire CT, Revolution ACT, and MR Breast Scanning Devices Also to Be Manufactured in India for Global Markets

Currently,GE Healthcare has four manufacturing plants in Bangalore (also known as the Silicon Valley of India), focusing on the production and export services of more than 30 GE products.Radiating across the entire South Asian market, such as India, Bangladesh, Sri Lanka, Nepal, Maldives, and Bhutan. The latest one was established in March 2022, with India's Production Linked Incentive (PLI) scheme indicating an investment amount exceeding 1 billion rupees.

As the fourth largest medical device market in Asia after Japan, China, and South Korea, India is also one of the top 20 global medical device markets.Plans to become one of the top five manufacturing centers globally in terms of value and technology for medical devices within the next few years.The president of GE Healthcare and the chairman of GE Healthcare India unanimously believe that India is a high-potential, high-priority investment market.

GE Healthcare President and CEO Peter J. Arduini stated, "We will continue to invest in expanding India's domestic capabilities and its global influence in medical technology manufacturing and R&D. Today's announcement aligns with our strategic vision of delivering precision innovation worldwide and accelerating India's goal of becoming the 'Global Hub for Medical Technology Innovation and Manufacturing.'"

It is reported that,Wipro GE Healthcare in India is a joint venture between GE Precision Healthcare of the United States and Wipro Group of India.It is one of the most successful and longest-operating joint ventures in the region, as well as the largest medical technology company in South Asia.

The two parties established a partnership in 1990, and later inWipro GE Healthcare was officially established in 2009, and it was announced that all independent departments and factories of GE Healthcare in India would be integrated under this company.

The integrated GE India has 1,200 employees and is the sole supplier of GE Healthcare in India. However, at that time, the manufacturing capacity of the GE India plant was not high.GE Healthcare plans to gradually produce 50-75% of its healthcare products in its Indian joint venture within five years.

As one of the first medical technology companies under "Make in India – For India and the World," GE Healthcare has high expectations for India's potential, thereforeInvested over 4 billion US dollars in R&D and manufacturing output over the past 30 years, and nurtured a robust local medical technology component manufacturing supplier ecosystem in China.Covering capabilities such as plastics, EMS, machining, castings, and 3D printing, contributing 1 million labor hours to suppliers. This investment will additionally extend 400,000 labor hours.

After perfecting the production chain, GE Healthcare India further expanded its capabilities to include research and development. In November last year, it launched nearly 40 new products, covering MRI, CT, PET/CT, ultrasound, and patient care equipment.

At the beginning of this month, the companyAnnounced plans to launch an equal number (40) of products this year to meet the needs of different types of customers across China.And indicated that more and more software applications based on artificial intelligence will be launched in the future.

According to the introduction,Currently, GE Healthcare in India already has 1,800 employees and is capable of manufacturing more than 30 different types of products. In the fiscal year 2023, revenue reached 71.35 billion rupees, with 40% of sales coming from within India.The company plans to double its workforce and further increase production capacity over the next decade.

As part of the investment plan, GE Healthcare India will build on its existing foundation,Additional production lines for Discovery IQ PET/CT, Revolution Aspire CT, Revolution ACT, and MR Breast Scanning equipment have been set up to supply markets outside of India.

Discovery IQ PET/CT

GE Discovery IQ PET/CT is currently the PET/CT product with the highest NEMA sensitivity (22 cps/kBq) in the industry.Achieves excellent detection capability for minute lesions. It also has the largest axial field of view coverage in the industry, providing a coverage range of up to 26 centimeters. In addition, the product utilizes Q.Clear full-coverage reconstruction technology, enabling fast and efficient reading, which doubles PET quantification accuracy (SUVmean) and image quality (SNR).

Revolution Aspire CT

The Revolution Aspire CT system, developed by GE Healthcare India specifically for the Indian government's Production Linked Incentive (PLI) scheme, aims to provide high-quality diagnostics across India, including in tier-two and tier-three cities.

Its system has been redesigned,Not only has it reduced the gantry rotation time by 20%, but it also features a new detector design and algorithm, as well as intelligent functions like Smart MAR, which can improve image quality by up to 30%., patient throughput increased by 50%.

Revolution ACT

Revolution ACT is the industry's first 32-slice precision CT,Integrating GE Healthcare's experience and core technologies in the high-end CT field, and incorporating the world's advanced low-dose technology, image quality enhancement technology, and 3D imaging technology, it boasts advantages such as fast scanning speed, wide coverage, high image quality, extensive spectral applications, and rich and accurate quantitative indicators.Capable of providing automatic efficacy analysis reports by comparing pre- and post-treatment results, it is an advanced imaging large-scale high-end device that realizes precision diagnosis and treatment.

As the largest country in the South Asian subcontinent, India's population is second only to China. In recent years, with the rapid development of India's national economy, the medical needs of the Indian people have surged, which has also made India's medical device market hold tremendous business opportunities.

However, unlike the pharmaceuticals industry which has seen years of booming local development,India currently faces a significant gap between the demand and supply of medical devices, with an import rate reaching 75%.This has led many capital giants and medical device giants to also continuously expand their presence in the Indian market.In addition to GE Healthcare, international medical device giants such as Medtronic, Philips, Stryker, and Omron have also established a presence in China.GE Healthcare has invested nearly 1 billion euros in building new factories in the past two years.

GE Healthcare

March 2022,GE Healthcare India announced plans to invest 1 billion rupees ($12.8 million) in a new manufacturing facility in Bangalore, India.The 35,000-square-foot facility, which is capable of operating 24/7, manufactures CT scanners, cathlab equipment, ultrasound machines, patient monitoring solutions, ECG machines, and ventilators. It is equipped with automated testers to evaluate the performance of medical devices. The plant currently has 35 employees in its workshop and is expected to increase its workforce to 100 people within the next two to three years.

Philips

And Philips has been operating factories in India for a long time,As early as 2008, Philips began its expansion in India's industrial and commercial sectors after acquiring Alpha X-ray Technologies and Meditronics in India, incorporating them as part of its imaging business.In line with its strategy to expand in India, Philips Healthcare has begun operations at its first imaging systems manufacturing facility in the country. The Philips Development and Manufacturing Center, located in Chakan, near Pune, approximately 200 kilometers east of Mumbai, focuses on diagnostic and interventional imaging solutions, initially developed for the Indian market and subsequently targeting global markets.

In May 2022, Philips India also announced the acquisition of 10 acres of land for further...Step up investment in India, namely, to establish a new R&D (Research and Development) center to expand the innovation capabilities in Pune.Further investment in India.

Medtronic

May 2023,Medtronic announces plans to invest 30 billion rupees (approximately US$350 million, equivalent to about RMB 2.486 billion),To expand its Engineering and Innovation Center (MEIC) in Hyderabad, located in the southern Indian state of Telangana. The MEIC currently employs over 800 people, primarily engineers, and with the additional investment, this number is expected to exceed 1,500 within the next five years. This investment will support key medical technology areas, including robotics, imaging and navigation, surgical technologies, and implant techniques.

OMRON

June 2023,Omron announces investment of INR 1.28 billion (approximately RMB 113 million) to establish its first medical device factory in Tamil Nadu, southern India. The factory is located in the Mahindra Industrial Park in Chennai, the capital of Tamil Nadu, and is planned to cover an area of 6.02 acres. It is expected to commence operations in March 2025, focusing on supplying blood pressure monitors to the domestic market in India. With the addition of the new factory, by 2030OMRONAiming to achieve a sales scale of approximately 5 million units in the Indian market.

--

The Indian medical device market was estimated to be around 3 billion US dollars in 2009 and is expected to reach 11 billion US dollars by 2020. In April 2023, the Indian government announced the National Medical Device Policy with the goal of growing the industry to 50 billion US dollars annually within the next five years. Expanding operations and setting up manufacturing plants in India at this time will undoubtedly be a successful investment.

So, what development trends and challenges will GE Healthcare's layout in India bring in the future as the global medical industry continues to grow? Instrument Family will keep following up.

END

 

More exciting content

Welcome to follow WeChat Video Channel

Instrument Family

Related Reading

Tap for more!

$3.6 Billion Acquisition Makes Significant Progress

Powerful Collaboration: Samsung Focuses on AI Ultrasound

Minister of Commerce Meets with Global CEO of Medtronic: What Signal? How to Strategize?

XLEAP-SBS Brings a Brand-New Upgrade to NextSeq™ 1000/2000

In Debt of 269.5 Billion, Giant Steps into Medical Devices

After $7.4 Billion Acquisition, Monitoring Giant Announces Split

Top 100 Hard-Core Technology Enterprises in Shanghai 2024: United Imaging, MicroPort, Aohua...

Medtronic Lin Mao: Enhancing "Quality" with "Intelligence," Aiming to Become an "Insider" in China's Neurosurgery Market

Just now, Stryker announced the completion of a major acquisition

$5.07 Billion Sale: Century-Old Giant Exits Medical Device Business

BusinessBusiness cooperation email: qxzj@landianyiliao.com